Leqembi’s benefits continue to improve with longer use, study finds
By
Kristen Fischer
Jul 31, 2024
People with early-stage Alzheimer’s disease who take Leqembi can experience more benefits if they stay on it for three years, a new study shows.
Clinical Briefs for Friday, October 11
By
Alicia Lasek
Oct 10, 2019
Research sheds new light on how brain forms, recalls memories … FDA approves Dexcom G6 Pro continuous glucose monitor … Acute respiratory viral illness surveillance possible in long-term care: study...
Eli Lilly aims for dementia drug candidate’s approval in 2022; wants to ‘prioritize access’
By
Alicia Lasek
Aug 04, 2021
The Alzheimer’s disease-modifying drug donanemab is on track to be considered for full FDA approval by 2022, its developer said.
Scientists say they’ve zeroed in on a cause of Alzheimer’s
By
Alicia Lasek
Dec 03, 2021
Researchers from the University of California, Riverside say they have uncovered a reason why some people with plaques and tangles in their brains do not develop Alzheimer’s disease.
Generic for Viagra holds promise as Alzheimer’s disease treatment, Cleveland Clinic researchers say
Dec 08, 2021
Users of sildenafil are 69% less likely to develop Alzheimer’s disease than their peers who do not use the drug, investigators report. A clinical trial to confirm its benefits for Alzheimer’s patients...
Study: Having two copies of gene mutation linked to Alzheimer’s may cause onset
By
Kristen Fischer
May 07, 2024
A new study finds that possessing two copies of a specific gene mutation that’s common in Alzheimer’s disease may be the cause behind the disease in those people.